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To investigate an association between KI and WU 
polyomavirus (KIPyV and WUPyV) infections and CD4+ 
cell counts, we tested HIV-1–positive patients and blood 
donors. No association was found between cell counts and 
virus infections in HIV-1–positive patients. Frequency of 
KIPyV infection was similar for both groups. WUPyV was 
more frequent in HIV-1–positive patients.
BK and JC polyomaviruses are known to infect humans (1,2). Recently, the novel KI polyomavirus (KIPyV) 
and WU polyomavirus (WUPyV) have been identifi ed in 
respiratory secretions of children with signs of acute respi-
ratory disease (3,4). However, there is little evidence that 
these viruses are the causative agents of respiratory disease. 
The pathogenic role of these viruses in immunocompro-
mised patients is also unclear.
In a study that investigated human polyomaviruses in 
autopsy lymphoid tissue samples from patients who were 
positive for HIV, KIPyV was detected in 7.1% of immu-
nocompromised patients with AIDS and in 1.8% of non-
immunocompromised controls; WUPyV was detected in 
9.5% of patients with AIDS but not in controls (5). We de-
tected KIPyV and WUPyV in 3.2% and 1.6%, respectively, 
of plasma samples from HIV-1–infected patients (6). To 
determine an association between infection with KIPyV 
and WUPyV and CD4+ cell counts, we obtained plasma 
samples from HIV-1–positive patients having high and low 
CD4+ cell counts and a group of healthy controls and tested 
them for these 2 polyomaviruses.
The Study
Plasma specimens from 153 HIV-1–infected persons 
(75% male patients, median age 41.9 years, interquartile 
range 33.8–47.3 years) with high (110 persons) and low 
(43 persons) CD4+ counts and from 130 blood donors 
(80% male donors, median age 41 years, interquartile 
range 32–47.5 years) were obtained at the Foundation 
Polyclinic Tor Vergata in Rome, Italy, during 2004–2009. 
Of 153 HIV-1–infected patients, 74 were receiving highly 
active antiretroviral therapy: a nucleoside reverse tran-
scriptase inhibitor (NRTI) and a protease inhibitor (PI) (n 
= 35 patients); an integrase inhibitor (INI), an NRTI, and 
a PI (n = 7); a nonnucleoside-reverse transcriptase inhibi-
tor and an NRTI (n = 26); an INI and an NRTI (n = 2); an 
INI and an NNRTI (n = 2); a chemokine receptor type 5 
antagonist, an NRTI, and a PI (n = 1); and a chemokine 
receptor type 5 antagonist, an INI, and a nonnucleoside-
reverse transcriptase inhibitor (n = 1). Sixty patients did 
not receive any therapy. No information was available for 
19 patients. Additional information available for patients 
included HIV-1 viremia and co-infection with hepatitis B 
virus and hepatitis C virus.
Phylogenetic analysis of the small T antigen gene of 
KIPyV and WUPyV was performed as described (6,7). 
GenBank accession numbers of the sequences used in this 
analysis are shown in the online Appendix Table (www.
cdc.gov/EID/content/16/9/1482-appT.htm).
Total DNA was extracted from 0.2-mL plasma samples 
by using QIAamp DNA Mini Kit (QIAGEN, Milan, Italy) 
according to the manufacturer’s instructions and stored at 
–80°C until analysis. Amplifi cation of KIPyV and WUPyV 
was conducted as described (8,9). A standard curve was 
created in a 4-log range by using 1:10 serial dilutions of 
a virus-specifi c standard. The dynamic range was deter-
mined by using 10-fold dilutions (1010–100 copies/reac-
tion) of each sample. Sensitivity of the 2 methods, which 
corresponded to the lowest plasma dilution detectable at a 
frequency of 100%, was evaluated. The dynamic range was 
102–1010 for KIPyV and 101–1010 for WUPyV.
Statistical analysis was performed by using Epi Info 
version 3.5.1 software (Centers for Disease Control and 
Prevention, Atlanta, GA, USA). Odds ratios were deter-
mined for associations between infection with HIV and 
infection with KIPyV and WUPyV and other variables. 
Statistical signifi cance was assessed by calculating 95% 
confi dence intervals (CIs) and by using standard nonpara-
metric statistics.
Real-time PCR detected KIPyV and WUPyV in 4 
(2.6%) of 153 and 7 (4.6%) of 153 HIV-1–infected pa-
tients, respectively (Table 1). Of the 130 blood donors 
examined, 4 and 1 were positive for KIPyV (3.1%) and 
WUPyV (0.8%), respectively. For KIPyV, no differ-
ence was detected in the frequency of infection between 
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HIV-1–infected patients and blood donors. Patients infect-
ed with HIV-1 had a higher risk for infection with WUPyV 
infection than did blood donors. However, this difference 
showed borderline statistical signifi cance (odds ratio 6.15, 
95% CI 0.93–141; p = 0.054). For WUPyV-positive and 
KIPyV-positive patients, median CD4+ cell counts were 
308 cells/μL (95% CI 248–523 cells/μL) and 356 cells/μL 
(95% CI 270–517 cells/μL), respectively. No association 
was observed between CD4+ cell counts and risk for infec-
tion with KIPyV or WUPyV.
Median HIV-1 virus load in persons infected with 
WUPyV or KIPyV was 3,210 copies/mL (95% CI 108–
36,895 copies/mL) or 60,636 copies/mL (95% CI 2,791–
246,500 copies/mL), respectively. When HIV-1 virus 
load, CD4+ cell count, and co-infection with hepatitis 
B and C viruses were analyzed in patients infected with 
KIPyV or WUPyV, no association was found. Of 11 pa-
tients infected with KIPyV or WUPyV, 6 received high-
ly active antiretroviral therapy and 5 did not receive any 
therapy (Table 2).
Phylogenetic analysis showed that all WUPyVs identi-
fi ed in this study except WUV-IT4 are closely related to the 
WUV-IT3 strain identifi ed in an HIV-1 patient (6) (Figure). 
The KIPyV strains identifi ed are relatively distant from 
those identifi ed in another study (6), except for strain KIV-
RM23, which clusters with KIV-RM21 (6) (Figure).
Conclusions
KIPyV and WUPyV have been identifi ed in respiratory 
secretions of pediatric patients (3,4). New polyomaviruses 
have also been detected in immunocompromised patients 
(10–13). However, the pathogenic role of these polyoma-
viruses in immunocompromised patients is unclear. No as-
sociations were found between CD4+ cell counts in HIV-
1–positive patients and infection with KIPyV or WUPyV. 
Frequency of KIPyV infection for HIV-1–positive patients 
was similar to that for blood donors. However, frequency of 
WUPyV infection was higher for HIV-1–positive patients 
than for blood donors, although this difference showed bor-
derline signifi cance.
Detection of WUPyV did not show a correlation with 
virus load for HIV-1 or lower CD4+ cell counts. Sero-
prevalence of KIPyV and WUPyV in an adult population 
was 55% and 69%, respectively (14). The higher rate of 
infection for WUPyV may account for the higher rate of 
detection for WUPyV in our study population. In a previ-
ous study (6), prevalence of WUPyV in plasma of HIV-1
–positive patients was lower than that in our study. This 
difference may have been caused by the larger sample size 
in our study.
Phylogenetic analysis did not suggest circulation 
of specifi c KIPyV and WUPyV strains in HIV-1–posi-
tive patients. The KIPyVs identifi ed in this study cluster 
with those identifi ed in HIV-1–positive patients, and the 
WUPyVs identifi ed are closely related to the strain identi-
fi ed previously in an HIV-1–positive patient (6). However, 
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Table 1. Characteristics of 153 HIV+ persons tested for infection with WU and KI polyomaviruses, Italy, 2004–2009*† 
Characteristic WUPyV+, n = 7 WUPyV–, n = 146 KIPyV+, n = 4 KIPyV–, n = 149 
CD4+ cells/μL 
 <200 1 (14.3) 45 (30.8) 46 (30.9) 
 >200 6 (85.7) 101 (69.2) 4 (100) 103 (69.1) 
 Median (95% CI) 308 (248–523) 282 (153–378) 356 (270–517) 281 (154–378) 
Virus load, copies/mL 
 <100,000 7 (100) 99 (67.8) 2 (50) 104 (69.8) 
 >100,000 47 (32.2) 2 (50) 45 (30.2) 
 Median (95% CI) 3,210 (108–36,895) 37,460 (5,490?152,000) 60,636 (2,791–246,500) 34,905 (4,980–145,200) 
Co-infection
 Yes 2‡ (28.6) 29 (19.9) 2§ (50) 29 (19.5) 
 No 5 (71.4) 117 (80.1) 2 (50) 120 (80.5) 
*Values are no. (%) unless otherwise indicated. WUPvV, WU polyomavirus; KIPyV, KI polyomavirus; CI, confidence interval. 
†Of the 153 persons tested, 115 (75.2%) were men, 38 (24.8%) women. A total of 130 blood donors (104 [80%] men, 26 [20%] women) were also tested; 
1 (0.8%) was WUPyV+ and 4 (3.1%) were KIPyV+. 
‡Co-infection with hepatitis virus. 
§Co-infection with hepatitis C virus and hepatitis B virus. 
Table 2. Treatment regimens for 11 HIV-1–positive patients co-
infected with KI or WU polyomavirus, Italy, 2004–2009* 
Patient no. KIPyV WUPyV HAART 
1 + – None 
2 + – None 
3 + – None
4 + – NRTI: FTC, TDF; PI: ATV, RTV 
5 – + NNRTI: EFV; NRTI: 3TC, TDF 
6 – + NNRTI: NVP; NRTI: 3TC, AZT 
7 – + NRTI: 3TC, AZT; PI: ATV, RTV 
8 – + NNRTI: NVP; NRTI: ABC, TDF 
9 – + None 
10 – + NNRTI: EFV; NRTI: 3TC, D4T 
11 – + None 
*KIPyV, KI polyomavirus; WUPyV, WU polyomavirus; HAART, highly 
active antiretroviral therapy;  NRTI, nucleoside reverse transcriptase 
inhibitor; FTC, emtricitabine; TDF, tenofovir; PI, protease inhibitor; ATV, 
atazanavir; RTV, ritonavir; NNRTI, nonnucleoside reverse transcriptase 
inhibitor; EFV, Efavirenz; 3TC, lamivudine; NVP, nevirapine; AZT, 
azidothymidine; ABC, D4T, stavudine. 
these WUPyV strains also cluster with strain WUV-IT1 
and 2 strains identifi ed in stool samples (10).
Our study design and the complex nature of AIDS-
related disease do not enable one to make defi nitive conclu-
sions on the role of novel polyomaviruses in HIV-1–posi-
tive patients. However, our data seem to exclude an active 
role for KIPyV and WUPyV in HIV-1–positive patients.
We detected WUPyV and KIPyV in healthy persons 
and immunocompromised persons. BK and JC polyoma-
viruses persist in peripheral blood mononuclear cells in 
healthy persons (15). However, frequency of detection 
may vary from 0% to 90% of persons tested. This large 
variation may refl ect recent infection or virus reactivation 
in a subgroup of persons (15). Thus, detection of KIPyV 
and WUPy in blood cells of immunocompetent persons is 
needed to identify a possible hematologic reservoir.
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analysis of KI polyomavirus (KIPyV) 
and WU polyomavirus (WUPyV) small 
T antigen sequences. Strains identifi ed 
in this study are in boldface. The tree 
was rooted by using the midpoint rooting 
method. Branch lengths were estimated 
by using the best fi tting nucleotide 
substitution (Hasegawa, Kishino, and 
Yano) model according to a hierarchical 
likelihood ratio test (6,7) and were drawn 
to scale. Scale bar indicates 0.8 nt 
substitutions per site. Asterisks along the 
branches indicate signifi cant statistical 
support for the clade subtending that 
branch (p<0.001 by the zero-branch-
length test and bootstrap support 
>65%).
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